论文部分内容阅读
目的：简述甲磺酸培高利特的药理活性和临床疗效。方法：临床前药理研究主要与溴隐亭进行比较。Ⅰ期临床：对１７例健康自愿受试者耐受性和血催乳素作用进行研究。临床试验：２６２例帕金森患者合并美多巴用药６周；１３５例高催乳素患者用药３周与溴隐亭比较。结果：药理评价显示甲磺酸培高利特是一典型Ｄ受体激动剂。帕金森病治疗，随机双盲临床试验显示合用美多巴比安慰剂合用美多巴更为有效（Ｐ＜０．０１）；治疗高催乳素血症显示０．０５～０．１５ｍｇ／ｄ与溴隐亭２．５～１０ｍｇ／ｄ作用相等（Ｐ＞０．０５）。结论：甲磺酸培高利特是一治疗帕金森病和高催乳素血症有效且副作用较小的药物
Objective: To briefly describe the pharmacological activity and clinical efficacy of pergolide mesylate. Methods: Preclinical pharmacological studies were compared with bromocriptine. Phase I Clinical: Study of tolerance and prolactin action in 17 healthy volunteers. Clinical trials: 262 Parkinson’s patients with metoprolol for 6 weeks; 135 patients with high prolactin for 3 weeks compared with bromocriptine. Results: Pharmacological evaluation showed that pergolide mesylate is a typical D receptor agonist. Parkinson’s disease treatment, randomized, double-blind clinical trial showed that the combination of methdopa with metopal was more effective than placebo with metopar (P <0.01); treatment of hyperprolactinemia showed 0.05 ~ 0.15mg / d and Bromocriptine 2.5 ~ 10mg / d equal (P> 0.05). CONCLUSION: Peglitant mesylate is a potent and side-effect drug for the treatment of Parkinson’s disease and hyperprolactinemia